Characterization of humoral and cellular immune features of gamma-irradiated influenza vaccine

References

• Fischer WA 2nd, Gong M, Bhagwanjee S, Sevransky J. Global burden of influenza as a cause of cardiopulmonary morbidity and mortality. Glob Heart. 2014;9:325–36. doi:10.1016/j.gheart.2014.08.004.
   PubMedGoogle Scholar
• de Boer PT, Kelso JK, Halder N, Nguyen TP, Moyes J, Cohen C, Barr IG, Postma MJ, Milne GJ. The cost-effectiveness of trivalent and quadrivalent influenza vaccination in communities in South Africa, Vietnam and Australia. Vaccine. 2018;36:997–1007. doi:10.1016/j.vaccine.2017.12.073.
   PubMed Web of Science ®Google Scholar
• Carrillo-Santisteve P, Ciancio BC, Nicoll A, Lopalco PL. The importance of influenza prevention for public health. Hum Vaccin Immunother. 2012;8:89–95. doi:10.4161/hv.8.1.19066.
   PubMed Web of Science ®Google Scholar
• Krammer F. Novel universal influenza virus vaccine approaches. Curr Opin Virol. 2016;17:95–103. doi:10.1016/j.coviro.2016.02.002.
   PubMed Web of Science ®Google Scholar
• Kon TC, Onu A, Berbecila L, Lupulescu E, Ghiorgisor A, Kersten GF, Cui YQ, Amorij JP, Van der Pol L. Influenza vaccine manufacturing: effect of inactivation, splitting and site of manufacturing. Comparison of influenza vaccine production processes. PLoS One. 2016;11:e0150700. doi:10.1371/journal.pone.0150700.
   PubMed Web of Science ®Google Scholar
• Barry DW, Staton E, Mayner RE. Inactivated influenza vaccine efficacy: diminished antigenicity of split-product vaccines in mice. Infect Immun. 1974;10:1329–36.
   PubMed Web of Science ®Google Scholar
• Barry DW, Mayner RE, Staton E, Dunlap RC, Rastogi SC, Hannah JE, Blackburn RJ, Nortman DF, Graze PR. Comparative trial of influenza vaccines. I. Immunogenicity of whole virus and split product vaccines in man. Am J Epidemiol. 1976;104:34–46.
   PubMed Web of Science ®Google Scholar
• Ortbals DW, Liebhaber H. Comparison of immunogenicity of a whole virion and a subunit influenza vaccine in adults. J Clin Microbiol. 1978;8:431–34.
   PubMed Web of Science ®Google Scholar
• Moghaddam A, Olszewska W, Wang B, Tregoning JS, Helson R, Sattentau QJ, Openshaw PJ. A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines. Nat Med. 2006;12:905–07. doi:10.1038/nm1456.
   PubMed Web of Science ®Google Scholar
• Amanna IJ, Raue HP, Slifka MK. Development of a new hydrogen peroxide-based vaccine platform. Nat Med. 2012;18:974–79. doi:10.1038/nm.2763.
   PubMed Web of Science ®Google Scholar
• Skoble J, Beaber JW, Gao Y, Lovchik JA, Sower LE, Liu W, Luckett W, Peterson JW, Calendar R, Portnoy DA, et al. Killed but metabolically active Bacillus anthracis vaccines induce broad and protective immunity against anthrax. Infect Immun. 2009;77:1649–63. doi:10.1128/IAI.00530-08.
   PubMed Web of Science ®Google Scholar
• Dubensky TW Jr., Skoble J, Lauer P, Brockstedt DG. Killed but metabolically active vaccines. Curr Opin Biotechnol. 2012;23:917–23. doi:10.1016/j.copbio.2012.04.005.
   PubMed Web of Science ®Google Scholar
• Brockstedt DG, Bahjat KS, Giedlin MA, Liu W, Leong M, Luckett W, Gao Y, Schnupf P, Kapadia D, Castro G, et al. Killed but metabolically active microbes: a new vaccine paradigm for eliciting effector T-cell responses and protective immunity. Nat Med. 2005;11:853–60. doi:10.1038/nm1276.
   PubMed Web of Science ®Google Scholar
• Seo HS. Application of radiation technology in vaccines development. Clin Exp Vaccine Res. 2015;4:145–58. doi:10.7774/cevr.2015.4.2.145.
   PubMed Web of Science ®Google Scholar
• Choi E, Michalski CJ, Choo SH, Kim GN, Banasikowska E, Lee S, Wu K, An HY, Mills A, Schneider S, et al. First Phase I human clinical trial of a killed whole-HIV-1 vaccine: demonstration of its safety and enhancement of anti-HIV antibody responses. Retrovirology. 2016;13:82. doi:10.1186/s12977-016-0317-2.
   PubMed Web of Science ®Google Scholar
• Magnani DM, Harms JS, Durward MA, Splitter GA. Nondividing but metabolically active gamma-irradiated Brucella melitensis is protective against virulent B. melitensis challenge in mice. Infect Immun. 2009;77:5181–89. doi:10.1128/IAI.00231-09.
   PubMed Web of Science ®Google Scholar
• Babb R, Chen A, Ogunniyi AD, Hirst TR, Kara EE, McColl SR, Alsharifi M, Paton JC. Enhanced protective responses to a serotype-independent pneumococcal vaccine when combined with an inactivated influenza vaccine. Clin Sci (Lond). 2017;131:169–80. doi:10.1042/CS20160475.
   PubMed Web of Science ®Google Scholar
• David SC, Lau J, Singleton EV, Babb R, Davies J, Hirst TR, McColl SR, Paton JC, Alsharifi M. The effect of gamma-irradiation conditions on the immunogenicity of whole-inactivated Influenza A virus vaccine. Vaccine. 2017;35:1071–79. doi:10.1016/j.vaccine.2016.12.044.
   PubMed Web of Science ®Google Scholar
• Alsharifi M, Furuya Y, Bowden TR, Lobigs M, Koskinen A, Regner M, Trinidad L, Boyle DB, Mullbacher A. Intranasal flu vaccine protective against seasonal and H5N1 avian influenza infections. PLoS One. 2009;4:e5336. doi:10.1371/journal.pone.0005336.
   PubMed Web of Science ®Google Scholar
• Takada A, Matsushita S, Ninomiya A, Kawaoka Y, Kida H. Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice. Vaccine. 2003;21:3212–18.
   PubMed Web of Science ®Google Scholar
• Kim HY, Kim SK, Seo HS, Jeong S, Ahn KB, Yun CH, Han SH. Th17 activation by dendritic cells stimulated with gamma-irradiated Streptococcus pneumoniae. Mol Immunol. 2018;101:344–52. doi:10.1016/j.molimm.2018.07.023.
   PubMed Web of Science ®Google Scholar
• Gomez Lorenzo MM, Fenton MJ. Immunobiology of influenza vaccines. Chest. 2013;143:502–10. doi:10.1378/chest.12-1711.
   PubMed Web of Science ®Google Scholar
• Herrera-Rodriguez J, Signorazzi A, Holtrop M, de Vries-idema J, Huckriede A. Inactivated or damaged? Comparing the effect of inactivation methods on influenza virions to optimize vaccine production. Vaccine. 2019;37:1630–37. doi:10.1016/j.vaccine.2019.01.086.
   PubMed Web of Science ®Google Scholar
• Gould VMW, Francis JN, Anderson KJ, Georges B, Cope AV, Tregoning JS. Nasal IgA provides protection against human influenza challenge in volunteers with low serum influenza antibody titre. Front Microbiol. 2017;8:900. doi:10.3389/fmicb.2017.00900.
   PubMed Web of Science ®Google Scholar
• Renegar KB, Small PA Jr., Boykins LG, Wright PF. Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract. J Immunol. 2004;173:1978–86. doi:10.4049/jimmunol.173.3.1978.
   PubMed Web of Science ®Google Scholar
• Huber VC, McKeon RM, Brackin MN, Miller LA, Keating R, Brown SA, Makarova N, Perez DR, Macdonald GH, McCullers JA. Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza. Clin Vaccine Immunol. 2006;13:981–90. doi:10.1128/CVI.00156-06.
   PubMed Web of Science ®Google Scholar
• Lanzavecchia A, Sallusto F. Regulation of T cell immunity by dendritic cells. Cell. 2001;106:263–66. doi:10.1016/s0092-8674(01)00455-x.
   PubMed Web of Science ®Google Scholar
• Hancock DG, Guy TV, Shklovskaya E, Fazekas de St Groth B. Experimental models to investigate the function of dendritic cell subsets: challenges and implications. Clin Exp Immunol. 2013;171:147–54. doi:10.1111/cei.12027.
   PubMed Web of Science ®Google Scholar
• Reitman M, Tonik EJ. Immunity to aerosol challenge in guinea pigs immunized with gamma-irradiated Venezuelan equine encephalitis vaccines. Appl Microbiol. 1971;21:688–92.
   PubMedGoogle Scholar
• Reitman M, Tribble HR Jr., Green L. Gamma-irradiated Venezuelan equine encephalitis vaccines. Appl Microbiol. 1970;19:763–67.
   PubMedGoogle Scholar
• Martin SS, Bakken RR, Lind CM, Garcia P, Jenkins E, Glass PJ, Parker MD, Hart MK, Fine DL. Comparison of the immunological responses and efficacy of gamma-irradiated V3526 vaccine formulations against subcutaneous and aerosol challenge with Venezuelan equine encephalitis virus subtype IAB. Vaccine. 2010;28:1031–40. doi:10.1016/j.vaccine.2009.10.126.
   PubMed Web of Science ®Google Scholar
• Miekka SI, Forng RY, Rohwer RG, MacAuley C, Stafford RE, Flack SL, MacPhee M, Kent RS, Drohan WN. Inactivation of viral and prion pathogens by gamma-irradiation under conditions that maintain the integrity of human albumin. Vox Sang. 2003;84:36–44.
   PubMed Web of Science ®Google Scholar
• Furuya Y, Regner M, Lobigs M, Koskinen A, Mullbacher A, Alsharifi M. Effect of inactivation method on the cross-protective immunity induced by whole ‘killed’ influenza A viruses and commercial vaccine preparations. J Gen Virol. 2010;91:1450–60. doi:10.1099/vir.0.018168-0.
   PubMed Web of Science ®Google Scholar
• Thavarajah R, Mudimbaimannar VK, Elizabeth J, Rao UK, Ranganathan K. Chemical and physical basics of routine formaldehyde fixation. J Oral Maxillofac Pathol. 2012;16:400–05. doi:10.4103/0973-029X.102496.
   PubMedGoogle Scholar
• Lee YH, Jang YH, Byun YH, Cheong Y, Kim P, Lee YJ, Lee YJ, Sung JM, Son A, Lee HM, et al. Green tea catechin-inactivated viral vaccine platform. Front Microbiol. 2017;8:2469. doi:10.3389/fmicb.2017.02469.
   PubMed Web of Science ®Google Scholar
• Fan YC, Chiu HC, Chen LK, Chang GJ, Chiou SS. Formalin inactivation of Japanese encephalitis virus vaccine alters the antigenicity and immunogenicity of a neutralization epitope in envelope protein domain III. PLoS Negl Trop Dis. 2015;9:e0004167. doi:10.1371/journal.pntd.0004167.
   PubMed Web of Science ®Google Scholar
• Petrie JG, Ohmit SE, Johnson E, Truscon R, Monto AS. Persistence of antibodies to influenza hemagglutinin and neuraminidase following one or two years of influenza vaccination. J Infect Dis. 2015;212:1914–22. doi:10.1093/infdis/jiv313.
   PubMed Web of Science ®Google Scholar
• Pilette C, Ouadrhiri Y, Godding V, Vaerman JP, Sibille Y. Lung mucosal immunity: immunoglobulin-A revisited. Eur Respir J. 2001;18:571–88. doi:10.1183/09031936.01.00228801.
   PubMed Web of Science ®Google Scholar
• Suzuki T, Ainai A, Hasegawa H. Functional and structural characteristics of secretory IgA antibodies elicited by mucosal vaccines against influenza virus. Vaccine. 2017;35:5297–302. doi:10.1016/j.vaccine.2017.07.093.
   PubMed Web of Science ®Google Scholar
• Tamura S, Kurata T. Defense mechanisms against influenza virus infection in the respiratory tract mucosa. Jpn J Infect Dis. 2004;57:236–47.
   PubMed Web of Science ®Google Scholar
• Bruhns P. Properties of mouse and human IgG receptors and their contribution to disease models. Blood. 2012;119:5640–49. doi:10.1182/blood-2012-01-380121.
   PubMed Web of Science ®Google Scholar
• Hocart MJ, Mackenzie JS, Stewart GA. The immunoglobulin G subclass responses of mice to influenza A virus: the effect of mouse strain, and the neutralizing abilities of individual protein A-purified subclass antibodies. J Gen Virol. 1989;70(Pt 9):2439–48. doi:10.1099/0022-1317-70-9-2439.
   PubMedGoogle Scholar
• Barnes N, Gavin AL, Tan PS, Mottram P, Koentgen F, Hogarth PM. FcgammaRI-deficient mice show multiple alterations to inflammatory and immune responses. Immunity. 2002;16:379–89.
   PubMed Web of Science ®Google Scholar
• Parham P. On the fragmentation of monoclonal IgG1, IgG2a, and IgG2b from BALB/c mice. J Immunol. 1983;131:2895–902.
   PubMed Web of Science ®Google Scholar
• Furuya Y. Return of inactivated whole-virus vaccine for superior efficacy. Immunol Cell Biol. 2012;90:571–78. doi:10.1038/icb.2011.70.
   PubMed Web of Science ®Google Scholar
• Govaert TM, Thijs CT, Masurel N, Sprenger MJ, Dinant GJ, Knottnerus JA. The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. JAMA. 1994;272:1661–65.
   PubMed Web of Science ®Google Scholar
• Brandriss MW, Betts RF, Mathur U, Douglas RG Jr. Responses of elderly subjects to monovalent A/USSR/77 (H1N1) and Trivalent A/USSR/77 (H1N1)-A/TEXAS/77 (H3N2)-B/Hong Kong/72 vaccines. Am Rev Respir Dis. 1981;124:681–84. doi:10.1164/arrd.1981.124.6.681.
   PubMedGoogle Scholar
• Gross PA, Quinnan GV Jr., Weksler ME, Setia U, Douglas RG Jr. Relation of chronic disease and immune response to influenza vaccine in the elderly. Vaccine. 1989;7:303–08.
   PubMed Web of Science ®Google Scholar
• Harty JT, Bevan MJ. Responses of CD8(+) T cells to intracellular bacteria. Curr Opin Immunol. 1999;11:89–93.
   PubMed Web of Science ®Google Scholar
• Datta SK, Okamoto S, Hayashi T, Shin SS, Mihajlov I, Fermin A, Guiney DG, Fierer J, Raz E. Vaccination with irradiated Listeria induces protective T cell immunity. Immunity. 2006;25:143–52. doi:10.1016/j.immuni.2006.05.013.
   PubMed Web of Science ®Google Scholar
• Hillaire ML, Nieuwkoop NJ, Boon AC, de Mutsert G, Vogelzang-van Trierum SE, Fouchier RA, Osterhaus AD, Rimmelzwaan GF. Binding of DC-SIGN to the hemagglutinin of influenza A viruses supports virus replication in DC-SIGN expressing cells. PLoS One. 2013;8:e56164. doi:10.1371/journal.pone.0056164.
   PubMed Web of Science ®Google Scholar
• van Montfoort N, van der Aa E, Woltman AM. Understanding MHC class I presentation of viral antigens by human dendritic cells as a basis for rational design of therapeutic vaccines. Front Immunol. 2014;5:182. doi:10.3389/fimmu.2014.00182.
   PubMed Web of Science ®Google Scholar
• Gotch F, McMichael A, Smith G, Moss B. Identification of viral molecules recognized by influenza-specific human cytotoxic T lymphocytes. J Exp Med. 1987;165:408–16.
   PubMed Web of Science ®Google Scholar
• Wahl A, Schafer F, Bardet W, Buchli R, Air GM, Hildebrand WH. HLA class I molecules consistently present internal influenza epitopes. Proc Natl Acad Sci U S A. 2009;106:540–45. doi:10.1073/pnas.0811271106.
   PubMed Web of Science ®Google Scholar
• Kitler ME, Gavinio P, Lavanchy D. Influenza and the work of the World Health Organization. Vaccine. 2002;20:S5–14.
   PubMed Web of Science ®Google Scholar
• Alonso WJ, Yu C, Viboud C, Richard SA, Schuck-Paim C, Simonsen L, Mello WA, Miller MA. A global map of hemispheric influenza vaccine recommendations based on local patterns of viral circulation. Sci Rep. 2015;5:17214. doi:10.1038/srep17214.
   PubMed Web of Science ®Google Scholar
• Soema PC, van Riet E, Kersten G, Amorij JP. Development of cross-protective influenza a vaccines based on cellular responses. Front Immunol. 2015;6:237. doi:10.3389/fimmu.2015.00237.
   PubMed Web of Science ®Google Scholar
• Mullbacher A, Ada GL, Hla RT. Gamma-irradiated influenza A virus can prime for a cross-reactive and cross-protective immune response against influenza A viruses. Immunol Cell Biol. 1988;66(Pt 2):153–57. doi:10.1038/icb.1988.19.
   PubMedGoogle Scholar
• Berlanda Scorza F, Tsvetnitsky V, Donnelly JJ. Universal influenza vaccines: shifting to better vaccines. Vaccine. 2016;34:2926–33. doi:10.1016/j.vaccine.2016.03.085.
   PubMed Web of Science ®Google Scholar
• Ulmer JB, Donnelly JJ, Parker SE, Rhodes GH, Felgner PL, Dwarki VJ, Gromkowski SH, Deck RR, DeWitt CM, Friedman A, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science. 1993;259:1745–49.
   PubMed Web of Science ®Google Scholar
• Ulmer JB, Fu TM, Deck RR, Friedman A, Guan L, DeWitt C, Liu X, Wang S, Liu MA, Donnelly JJ, et al. Protective CD4+ and CD8+ T cells against influenza virus induced by vaccination with nucleoprotein DNA. J Virol. 1998;72:5648–53.
   PubMed Web of Science ®Google Scholar
• Song JM, Wang BZ, Park KM, Van Rooijen N, Quan FS, Kim MC, Jin HT, Pekosz A, Compans RW, Kang SM. Influenza virus-like particles containing M2 induce broadly cross protective immunity. PLoS One. 2011;6:e14538. doi:10.1371/journal.pone.0014538.
   PubMed Web of Science ®Google Scholar